Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma

Completed · Phase 2

Conditions studied: Sarcoma

In brief

RATIONALE: Bortezomib may stop the growth of cancer by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who have advanced or metastatic sarcoma.

Key facts

Study ID

NCT00027716

Run by

Memorial Sloan Kettering Cancer Center

Starts

2001-10-01

Expected to finish

2004-05-01

Last updated by the study team

2013-06-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Colorado Cancer Center at University of Colorado Health Sciences Center — Aurora, Colorado, United States
• Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• University of Chicago Cancer Research Center — New York, New York, United States
• Albert Einstein College of Medicine — The Bronx, New York, United States
• Abramson Cancer Center at University of Pennsylvania Medical Center — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.